Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
ALTEX ; 38(1): 82-94, 2021.
Article in English | MEDLINE | ID: mdl-32754773

ABSTRACT

Recently, 3D in vitro cancer models have become important alternatives to animal tests for establishing the efficacy of anticancer treatments. In this work, 3D SKOV-3 cell-laden alginate hydrogels were established as ovarian tumor models and cultured within a fluid-dynamic bioreactor (MIVO®) device able to mimic the capillary flow dynamics feeding the tumor. Cisplatin efficacy tests were performed within the device over time and compared with (i) the in vitro culture under static conditions and (ii) a xenograft mouse model with SKOV-3 cells, by monitoring and measuring cell proliferation or tumor regression, respectively, over time. After one week of treatment with 10 µM cisplatin, viability of cells within the 3D hydrogels cultured under static conditions remained above 80%. In contrast, the viability of cells within the 3D hydrogels cultured within dynamic MIVO® decreased by up to 50%, and very few proliferating Ki67-positive cells were observed through immunostaining. Analysis of drug diffusion, confirmed by computational analysis, explained that these results are due to different cisplatin diffusion mechanisms in the two culture conditions. Interestingly, the outcome of the drug efficacy test in the xenograft model was about 44% of tumor regression after 5 weeks, as predicted in a shorter time in the fluid-dynamic in vitro tests carried out in the MIVO® device. These results indicate that the in vivo-like dynamic environment provided by the MIVO® device allows to better model the 3D tumor environment and predict in vivo drug efficacy than a static in vitro model.


Subject(s)
Animal Testing Alternatives , Antineoplastic Agents/therapeutic use , Bioreactors , Cisplatin/therapeutic use , Ovarian Neoplasms/drug therapy , Animals , Cell Line, Tumor , Cell Survival/drug effects , Female , Humans , Mice , Neoplasms, Experimental
2.
Mol Cell Biochem ; 276(1-2): 61-9, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16132686

ABSTRACT

Antisense and antigene oligonucleotides (ONs) are attractive drugs for gene therapy, but major limiting factors for their routine use are inefficient cellular uptake and low accessibility to the target sites. Adding various lipophilic conjugates to the ON improves intracellular delivery as has been previously reported. We studied the cellular delivery of various ON modifications, as well as their cytosolic and nuclear distribution in mammalian Hep2-EGFP-NLS cell line. We compared uptake efficacy of ON and LNA, both conjugated with cholesterol at the 5' end. All ONs were 3' labeled with fluorescent Cy 5 dye. We made a comparison of the ONs uptake efficacy and the kinetics, both adding ONs to the culture medium, and using streptolysin-O (SL-O) permeabilization. The cellular uptake of each ON used in this study was visualized by fluorescent microscopy. We confirmed the results by FACS analysis. We determined the ratio between initial ON-chol concentration (0.4 microM) and the final amount in nucleus.SL-O can highly improve kinetics of ON delivery; not only into the cytoplasm but also to the nucleus, the presumed site of antigene ON action. The most effective nuclear uptake was observed when ON conjugated with cholesterol (ON-chol) and SL-O was used. Nuclear distribution of ON was reached within few minutes. In contrast, ON simply added to the medium reached cytoplasm only and the process of delivery took several hours.


Subject(s)
Cell Nucleus/drug effects , Cholesterol/chemistry , Oligonucleotides, Antisense/chemistry , Oligonucleotides, Antisense/metabolism , Oligonucleotides/chemistry , Oligonucleotides/metabolism , Streptolysins/pharmacology , Bacterial Proteins/pharmacology , Biological Transport/drug effects , Cell Line , Cell Nucleus/metabolism , Cells, Cultured , Cholesterol/metabolism , Cytoplasm/drug effects , Cytoplasm/metabolism , Flow Cytometry , Humans , Microscopy, Fluorescence
3.
Oncogene ; 24(47): 6993-7001, 2005 Oct 27.
Article in English | MEDLINE | ID: mdl-16007137

ABSTRACT

Control of cell proliferation and differentiation by the retinoblastoma protein (pRb) depends on its interactions with key cellular substrates. Available data indicate that pRb and the transcription factor Pax 8 play a crucial role in the differentiation of thyroid follicular cells. In this study, we show that pRb takes part in the complex assembled on the thyroperoxidase gene promoter acting as a transcriptional coactivator of Pax 8. Accordingly, pRb interacts with and potentiates Pax 8 transcriptional activity. In addition, we show that the downregulation of pRb gene expression, in thyrocytes, through RNA interference results in a reduction of the thyroperoxidase gene promoter activity mediated by the Pax 8-binding site. In agreement with these results and with the ability of the adenoviral protein E1A to bind pRb, we show that E1A downregulates Pax 8 activity and that such inhibition requires the E1A-Rb interaction. Furthermore, we show that the Pax 8/pRb synergy plays a role on the sodium/iodide symporter gene expression as well.


Subject(s)
DNA-Binding Proteins/metabolism , Gene Expression Regulation , Iodide Peroxidase/genetics , Nuclear Proteins/metabolism , Promoter Regions, Genetic , Retinoblastoma Protein/metabolism , Trans-Activators/physiology , Adenovirus E1A Proteins/metabolism , Binding Sites , Cells, Cultured , Chromatin Immunoprecipitation , DNA-Binding Proteins/genetics , Glutathione Transferase/genetics , Glutathione Transferase/metabolism , Humans , Nuclear Proteins/genetics , PAX8 Transcription Factor , Paired Box Transcription Factors , Protein Binding , Protein Interaction Mapping , RNA Interference , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Retinoblastoma Protein/antagonists & inhibitors , Retinoblastoma Protein/genetics , Symporters/metabolism , Thyroid Gland/cytology , Thyroid Gland/metabolism , Trans-Activators/genetics , Trans-Activators/metabolism , Transcriptional Activation
4.
Acta Medica (Hradec Kralove) ; 47(3): 151-6, 2004.
Article in English | MEDLINE | ID: mdl-15568730

ABSTRACT

This review deals with the antigene strategy whereby an oligonucleotide binds to the major or minor groove of double helical DNA where it forms a local triple helix. Preoccupation of this article is triplex-forming oligonucleotides (TFO). These are short, synthetic single-stranded DNAs that recognize polypurine:polypyrimidine regions in double stranded DNA in a sequence-specific manner and form triplex. Therefore, the mechanisms for DNA recognition by triple helix formation are discussed, together with main characteristics of TFO and also major obstacles that remain to be overcome are highlighted. TFOs can selectively inhibit gene expression at the transcriptional level or repair genetic defect by direct genome modification in human cells. These qualities makes TFO potentially powerful therapeutic tool for gene repair and/or expression regulation.


Subject(s)
DNA , Gene Expression Regulation , Gene Targeting , Oligoribonucleotides , DNA/chemistry , DNA/metabolism , Minoxidil , Nucleic Acid Conformation , Nylons/chemistry , Nylons/metabolism , Oligoribonucleotides/chemistry , Oligoribonucleotides/metabolism , Protein Binding , Pyrimidines/chemistry , Pyrimidines/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL